Severe Combined Immunodeficiency (SCID)


Severe combined immunodeficiency (SCID) is a group of disorders characterized by the absence of both humoral and cellular immunity. Infants with SCID die of infections by age 2 years unless immunity is reconstituted by treatment. The defining characteristic for SCID is always a severe defect in T cell production and function, with defects in B-lymphocytes as a primary or secondary problem and, in some genetic types, in NK cell production as well. SCID is also commonly known as the “bubble boy” disease.


Infants generally have a normal physical examination result before the onset of infection. The pathophysiology and molecular biology vary among different forms of SCID, however, the lack of T-cell and B-cell function is the common endpoint in all forms of SCID. Lymphopenia usually occurs from the absence of T cell, and sometimes from the absence of natural killer cells. Functional antibodies are decreased or absent. Infections are usually serious, and may include pneumonia, meningitis or bloodstream infections with average age at the onset of symptoms at 2 months.


T-cell Receptor Excision circles (TRECs) are circular DNA fragments generated during T-cell receptor rearrangement. In healthy neonates, TRECs are made in large numbers, while in infants with SCID they are barely detectable. Following PCR amplification TREC copy number in blood can be used to distinguish T-cell lymphopenic SCID infants from healthy babies. However, low TRECs copy numbers can also be the results of other immunodeficiency, such as DiGeorge Syndrome, and sometimes as a result of the use of immunosuppression drugs. Confirmatory tests are needed for the diagnosis of SCID and for the determination of the form of SCID.


Infections are treated with specific antibiotic, antifungal, and antiviral agents and administration of intravenous immunoglobulin. Restoration of a functional immune system is essential. The preferred treatment is bone marrow/stem cell transplantation. Early detection and treatment can result in markedly improved survival rates. Enzyme replacement therapy is available for adenosine deaminase deficiency (a form of SCID). Gene therapy is still in the experimental phase.


SCID occurs in approximately 1 in 50,000-100,000 live births. Over 10 different genetic defects have been identified that account for SCID in humans. The most common type is linked to the X chromosome, making this form affect only males. This X-linked form accounts for approximately 50% of SCID cases. Other forms of SCID usually follow an autosomal recessive inheritance pattern or are the result of spontaneous mutations. Approximately 25% of the patients with an autosomal recessive SCID are JAK3 deficient, and 40% are adenosine deaminase deficient.


a. American College of Medical Genetics, Newborn Screening ACT Sheet, Severe Combined Immunodeficiency (SCID) and Conditions Associated with T Cell Lymphopenia,

b. Buckley, Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution, Annu Rev Immunol, 2004

c. Kwan and Puck, History and Current Status of Newborn Screening for Severe Combined Immunodeficiency, Semin Perinatol, 2015

d. van der Spek et al., TREC Based Newborn Screening for Severe Combined Immunodeficiency Disease: A Systematic Review, J Clin Immunol, 2015

e. Puck et al., Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States, JAMA ,2014

f. Serana et al, Use of V(D)J recombination exicision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies, Journal of Translational Medicine, 2013


Instruments for Severe Combined Immunodeficiency (SCID)

EONIS™ Platform

EONIS™ Platform

A complete system for SMA, SCID & XLA screening, from sample to results. The design of the EONIS assay and system enable automation without compromising the sample traceability from punch to result.

Compatible Kits



EONIS™ DNA Extraction kit


Related Articles & Resources

First SMA baby identified with our screening solutions in Australia
26 Apr 2021

First SMA baby identified with our screening solutions in Australia

A newborn baby has been identified as having SMA (spinal muscular atrophy) in Westmead Children’s Hospital in Australia, using a 4-plex SMA, SCID and XLA laboratory developed test
Multiplex Real-time PCR Newborn Screening Assay to Simultaneously Identify Spinal Muscular Atrophy and Severe Combined Immunodeficiency
26 May 2021

Multiplex Real-time PCR Newborn Screening Assay to Simultaneously Identify Spinal Muscular Atrophy and Severe Combined Immunodeficiency

Professor Mei Baker discusses Identifying Spinal Muscular Atrophy and Severe Combined Immunodeficiency using Real-time PCR newborn screening

Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations please consult your local health care professionals.



Take the next step


Speak with a sales person

Talk to one of our product experts about the right solutions for you.

Contact us today

View more resources

Explore our articles and resources section for the latest information.

Learn More

Read the lastest news

Sign up for our newsletter to find out about the latest news.

Sign up
Spin gif